Torasemid w postaci dożylnej w leczeniu ostrej niewydolności serca – doświadczenia ośrodka zabrzańskiego. Opis przypadku Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2019
Słowa kluczowe:
ostra niewydolność serca, zastój, terapia, diuretyki pętlowe, torasemid, furosemid
##plugins.themes.bootstrap3.article.main##
Abstrakt
Niewydolność serca to zespół objawowy, w którym dominującym objawem jest zastój narządowy. W leczeniu zastoju kluczową rolę odgrywają diuretyki. W ostrej fazie niewydolności serca stosuje się głównie leki pętlowe podawane drogą dożylną. Furosemid i torasemid są najczęściej wykorzystywane w tym schorzeniu w naszym kraju. Leki te poza wspólnym mechanizmem działania mają wiele odmiennych cech, co można wykorzystywać w praktyce klinicznej.
Szybkość powrotu płynu z przestrzeni pozakomórkowej do naczyń, nazywana szybkością refillingu, jest zróżnicowana w różnych fenotypach niewydolności serca. Cecha ta ma zasadnicze znaczenie zarówno dla skuteczności, jak i bezpieczeństwa leczenia. Przekroczenie szybkości refillingu przez szybkość diurezy może spowodować względną hipowolemię i prowadzić do niekorzystnych konsekwencji.
W pracy przedstawiono przypadek kliniczny chorego, u którego niedostosowanie szybkości diurezy wywołanej furosemidem do szybkości refillingu było prawdopodobnym podłożem powikłań. Zaprezentowano sposób rozwiązania tego problemu w praktyce poprzez podanie bardziej dostosowanego do sytuacji klinicznej torasemidu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Nowak, J., Buczkowska, M., Zbrojkiewicz , E., Mroczek , A., Gąsior, M., & Rozentryt, P. (2019). Torasemid w postaci dożylnej w leczeniu ostrej niewydolności serca – doświadczenia ośrodka zabrzańskiego. Opis przypadku. Medycyna Faktów , 12(3(44), 186-195. https://doi.org/10.24292/01.MF.0319.1
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Ponikowski P., Voors A., Anker S. et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Pol. Heart J. 2016; 74(10): 1037-1147. DOI: 10.5603/KP.2016.0141.
2. Sullivan M.J., Knight J.D., Higginbotham M.B., Cobb F.R.: Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure. Circulation 1989; 80(4): 769-781.
3. Cooper L.B., Lippmann S.J., DiBello J.R. et al.: The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. Am. J. Cardiol. 2019 May 25. pii: S0002-9149(19)30597-1. DOI: 10.1016/j.amjcard.2019.05.030. [Epub ahead of print].
4. Yancy Clyde W., Jessup M., Bozkurt B. et al.: 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136(6): e137-e161.
5. Domanski M., Norman J., Pitt B. et al.: Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J. Am. Coll. Cardiol. 2003; 42(4): 705-708.
6. Faris R.F., Flather M., Purcell H. et al.: Diuretics for heart failure. Cochrane Database of Syst. Rev. 2012 Feb 15; (2): CD003838. DOI: 10.1002/14651858.CD003838.pub3.
7. Mullens W., Damman K., Harjola V.P. et al.: The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2019; 21(2): 137-155.
8. Islam M.S.: The Art and Science of Using Diuretics in the Treatment of Heart Failure in Diverse Clinical Settings. In: Islam MS, editor. Heart Failure: From Research to Clinical Practice: Volume 3. Cham: Springer International Publishing; 2018: 47-65.
9. Somasekharan S., Tanis J., Forbush B.: Loop diuretic and ion-binding residues revealed by scanning mutagenesis of transmembrane helix 3 (TM3) of Na-K-Cl cotransporter (NKCC1). J. Biol. Chem. 2012; 287(21): 17308-17317.
10. Oppermann M., Hansen P.B., Castrop H., Schnermann J.: Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice. Am. J. Phys. Ren. Phys. 2007; 293(1): F279-F87.
11. Felker G.M., Mentz R.J.: Diuretics and Ultrafiltration in Acute Decompensated Heart Failure. J. Am. Coll. Cardiol. 2012; 59(24): 2145-2153.
12. Knauf H., Mutschler E., Velazquez H., Giebisch G.: Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis. Eur. J. Clin. Pharmacol. 2009; 65(5): 465-472.
13. Boyle A., Sobotka P.A.: Redefining the Therapeutic Objective in Decompensated Heart Failure: Hemoconcentration as a Surrogate for Plasma Refill Rate. J. Card. Fail. 2006; 12(4): 247-249.
14. Miller W.L., Mullan B.P.: Understanding the Heterogeneity in Volume Overload and Fluid Distribution in Decompensated Heart Failure Is Key to Optimal Volume Management: Role for Blood Volume Quantitation. JACC Heart Fail. 2014; 2(3): 298-305.
15. Figueras J., Weil M.H.: Blood volume prior to and following treatment of acute cardiogenic pulmonary edema. Circulation 1978; 57(2): 349-355.
16. Miller W.L., Mullan B.P.: Volume Overload Profiles in Patients With Preserved and Reduced Ejection Fraction Chronic Heart Failure: Are There Differences? A Pilot Study. JACC Heart Fail. 2016; 4(6): 453-459.
17. Miller W.L., Mullan B.P.: Understanding the Heterogeneity in Volume Overload and Fluid Distribution in Decompensated Heart Failure Is Key to Optimal Volume Management Role for Blood Volume Quantitation. JACC Heart Fail. 2014; 2(3): 298-305.
18. Senthong V., Kirsop J.L., Tang W.H.W.: Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Curr. Heart Fail. Rep. 2017; 14(2): 106-116.
19. Shah S.J., Kitzman D.W., Borlaug B.A. et al.: Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation 2016; 134(1): 73-90.
20. Hodson D.Z., Griffin M., Mahoney D. et al.: Natriuretic Response Is Highly Variable and Associated With 6-Month Survival: Insights From the ROSE-AHF Trial. JACC Heart Fail. 2019; 7(5): 383-391.
21. Girerd N., Seronde M.F., Coiro S. et al.: Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. JACC Heart Fail. 2018; 6(4): 273-285.
22. Ng K.T., Yap J.L.L.: Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials. Anaesthesia 2018; 73(2): 238-247.
23. Damman K., Kjekshus J., Wikstrand J. et al.: Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur. J. Heart Fail. 2016; 18(3): 328-336.
24. Catlin J.R., Adams C.B., Louie D.J. et al.: Aggressive Versus Conservative Initial Diuretic Dosing in the Emergency Department for Acute Decompensated Heart Failure. Ann. Pharmacother. 2018; 52(1): 26-31.
25. Woodruff A.E., Kelley A.M., Hempel C.A. et al.: Discharge Diuretic Dose and 30-Day Readmission Rate in Acute Decompensated Heart Failure. Ann. Pharmacother. 2016; 50(6): 437-445.
26. Okabe T., Yakushiji T., Kido T. et al.: The association between high-dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure. ESC Heart Fail. 2017; 5(1): 87-94.
27. Parén P., Dahlström U., Edner M. et al.: Association of diuretic treatment at hospital discharge in patients with heart failure with all-cause shortand long-term mortality: A propensity score-matched analysis from SwedeHF. Int. J. Cardiol. 2018; 257: 118-124.
28. Testani J.M., Chen J., McCauley B.D. et al.: Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and Survival. Circulation 2010; 122(3): 265-272.
29. Testani J.M., Brisco M.A., Chen J. et al.: Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival importance of sustained decongestion. J. Am. Coll. Cardiol. 2013; 62(6): 516-524.
30. Brisco M.A., Coca S.G., Chen J. et al.: Blood urea nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure. Circ. Heart Fail. 2013; 6(2): 233-239.
31. Koomans H.A., Geers A.B., Dorhout Mees E.J.: Plasma volume recovery after ultrafiltration in patients with chronic renal failure. Kidney Int. 1984; 26(6): 848-854.
32. Bilchick K.C., Chishinga N., Parker A.M. et al.: Plasma Volume and Renal Function Predict Six-Month Survival after Hospitalization for Acute Decompensated Heart Failure. Cardiorenal Med. 2018; 8(1): 61-70.
33. Shah S., Pitt B., Brater D.C. et al.: Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action. J. Am. Heart Assoc. 2017; 6(10): e006135.
34. Kasama S., Toyama T., Kurabayashi M.: Comparative effects of long and short-acting loop diuretics on mortality in patients with chronic heart failure. Int. J. Cardiol. 2017; 244: 242-244.
2. Sullivan M.J., Knight J.D., Higginbotham M.B., Cobb F.R.: Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Muscle blood flow is reduced with maintenance of arterial perfusion pressure. Circulation 1989; 80(4): 769-781.
3. Cooper L.B., Lippmann S.J., DiBello J.R. et al.: The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. Am. J. Cardiol. 2019 May 25. pii: S0002-9149(19)30597-1. DOI: 10.1016/j.amjcard.2019.05.030. [Epub ahead of print].
4. Yancy Clyde W., Jessup M., Bozkurt B. et al.: 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136(6): e137-e161.
5. Domanski M., Norman J., Pitt B. et al.: Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J. Am. Coll. Cardiol. 2003; 42(4): 705-708.
6. Faris R.F., Flather M., Purcell H. et al.: Diuretics for heart failure. Cochrane Database of Syst. Rev. 2012 Feb 15; (2): CD003838. DOI: 10.1002/14651858.CD003838.pub3.
7. Mullens W., Damman K., Harjola V.P. et al.: The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2019; 21(2): 137-155.
8. Islam M.S.: The Art and Science of Using Diuretics in the Treatment of Heart Failure in Diverse Clinical Settings. In: Islam MS, editor. Heart Failure: From Research to Clinical Practice: Volume 3. Cham: Springer International Publishing; 2018: 47-65.
9. Somasekharan S., Tanis J., Forbush B.: Loop diuretic and ion-binding residues revealed by scanning mutagenesis of transmembrane helix 3 (TM3) of Na-K-Cl cotransporter (NKCC1). J. Biol. Chem. 2012; 287(21): 17308-17317.
10. Oppermann M., Hansen P.B., Castrop H., Schnermann J.: Vasodilatation of afferent arterioles and paradoxical increase of renal vascular resistance by furosemide in mice. Am. J. Phys. Ren. Phys. 2007; 293(1): F279-F87.
11. Felker G.M., Mentz R.J.: Diuretics and Ultrafiltration in Acute Decompensated Heart Failure. J. Am. Coll. Cardiol. 2012; 59(24): 2145-2153.
12. Knauf H., Mutschler E., Velazquez H., Giebisch G.: Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis. Eur. J. Clin. Pharmacol. 2009; 65(5): 465-472.
13. Boyle A., Sobotka P.A.: Redefining the Therapeutic Objective in Decompensated Heart Failure: Hemoconcentration as a Surrogate for Plasma Refill Rate. J. Card. Fail. 2006; 12(4): 247-249.
14. Miller W.L., Mullan B.P.: Understanding the Heterogeneity in Volume Overload and Fluid Distribution in Decompensated Heart Failure Is Key to Optimal Volume Management: Role for Blood Volume Quantitation. JACC Heart Fail. 2014; 2(3): 298-305.
15. Figueras J., Weil M.H.: Blood volume prior to and following treatment of acute cardiogenic pulmonary edema. Circulation 1978; 57(2): 349-355.
16. Miller W.L., Mullan B.P.: Volume Overload Profiles in Patients With Preserved and Reduced Ejection Fraction Chronic Heart Failure: Are There Differences? A Pilot Study. JACC Heart Fail. 2016; 4(6): 453-459.
17. Miller W.L., Mullan B.P.: Understanding the Heterogeneity in Volume Overload and Fluid Distribution in Decompensated Heart Failure Is Key to Optimal Volume Management Role for Blood Volume Quantitation. JACC Heart Fail. 2014; 2(3): 298-305.
18. Senthong V., Kirsop J.L., Tang W.H.W.: Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives. Curr. Heart Fail. Rep. 2017; 14(2): 106-116.
19. Shah S.J., Kitzman D.W., Borlaug B.A. et al.: Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction. Circulation 2016; 134(1): 73-90.
20. Hodson D.Z., Griffin M., Mahoney D. et al.: Natriuretic Response Is Highly Variable and Associated With 6-Month Survival: Insights From the ROSE-AHF Trial. JACC Heart Fail. 2019; 7(5): 383-391.
21. Girerd N., Seronde M.F., Coiro S. et al.: Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. JACC Heart Fail. 2018; 6(4): 273-285.
22. Ng K.T., Yap J.L.L.: Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials. Anaesthesia 2018; 73(2): 238-247.
23. Damman K., Kjekshus J., Wikstrand J. et al.: Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction. Eur. J. Heart Fail. 2016; 18(3): 328-336.
24. Catlin J.R., Adams C.B., Louie D.J. et al.: Aggressive Versus Conservative Initial Diuretic Dosing in the Emergency Department for Acute Decompensated Heart Failure. Ann. Pharmacother. 2018; 52(1): 26-31.
25. Woodruff A.E., Kelley A.M., Hempel C.A. et al.: Discharge Diuretic Dose and 30-Day Readmission Rate in Acute Decompensated Heart Failure. Ann. Pharmacother. 2016; 50(6): 437-445.
26. Okabe T., Yakushiji T., Kido T. et al.: The association between high-dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure. ESC Heart Fail. 2017; 5(1): 87-94.
27. Parén P., Dahlström U., Edner M. et al.: Association of diuretic treatment at hospital discharge in patients with heart failure with all-cause shortand long-term mortality: A propensity score-matched analysis from SwedeHF. Int. J. Cardiol. 2018; 257: 118-124.
28. Testani J.M., Chen J., McCauley B.D. et al.: Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and Survival. Circulation 2010; 122(3): 265-272.
29. Testani J.M., Brisco M.A., Chen J. et al.: Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival importance of sustained decongestion. J. Am. Coll. Cardiol. 2013; 62(6): 516-524.
30. Brisco M.A., Coca S.G., Chen J. et al.: Blood urea nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure. Circ. Heart Fail. 2013; 6(2): 233-239.
31. Koomans H.A., Geers A.B., Dorhout Mees E.J.: Plasma volume recovery after ultrafiltration in patients with chronic renal failure. Kidney Int. 1984; 26(6): 848-854.
32. Bilchick K.C., Chishinga N., Parker A.M. et al.: Plasma Volume and Renal Function Predict Six-Month Survival after Hospitalization for Acute Decompensated Heart Failure. Cardiorenal Med. 2018; 8(1): 61-70.
33. Shah S., Pitt B., Brater D.C. et al.: Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action. J. Am. Heart Assoc. 2017; 6(10): e006135.
34. Kasama S., Toyama T., Kurabayashi M.: Comparative effects of long and short-acting loop diuretics on mortality in patients with chronic heart failure. Int. J. Cardiol. 2017; 244: 242-244.